Welcome to our dedicated page for Cuprina Holdings (Cayman) SEC filings (Ticker: CUPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cuprina Holdings (Cayman) Limited filings document a foreign private issuer developing and marketing biomedical products across chronic wounds, infertility, medical waste recycling and cosmeceuticals. Its Form 6-K reports furnish press releases and material updates on MEDIFLY regulatory classification, wound care collaborations, medical waste recycling licenses, scientific advisory activity and research-related announcements.
The company's regulatory record also covers annual general meeting materials, proxy voting matters, director elections, auditor appointments, an employee incentive plan, amended memorandum and articles of association, board and officer changes, and ordinary-share public-company governance. These filings provide formal disclosure around Cuprina's operating initiatives, governance structure, accounting oversight and capital-market reporting status.
Cuprina Holdings (Cayman) Limited has called a May 14, 2026 annual general meeting to vote on wide‑ranging governance and capital structure changes. The board seeks approval for a share consolidation affecting both Class A and Class B Ordinary Shares to help regain compliance with Nasdaq’s $1.00 minimum bid rule.
Shareholders are asked to increase Class B voting power from 10 to 100 votes per share, double authorised capital after the consolidation, adopt new second amended and restated constitutional documents, and approve the Cuprina 2026 Employee Incentive Plan covering up to 15% of Class A shares. A key proposal would authorise future financings that may exceed 20% of outstanding Class A Ordinary Shares or result in a change of control under Nasdaq rules, potentially diluting existing holders.
Cuprina Holdings (Cayman) LTD director files initial ownership report with the SEC. NG Wei Chean is identified as a director of CUPR, but this Form 3 excerpt shows no reported transactions or specific share or derivative holdings for this insider.
Cuprina Holdings reports a key regulatory milestone and a governance upgrade. Its 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority for MEDIFLY, a medical-grade maggot debridement therapy. The SFDA has categorized MEDIFLY as a Medical Device–Drug combination product, primarily regulated under the medical device framework. This classification enables Cuprina to finalize scientific and technical requirements needed for commercial distribution across Saudi Arabia’s healthcare network, supporting its Middle East and North Africa expansion strategy.
The company also strengthened its Medical and Scientific Advisory Board by appointing Dr. Enming Yong, a consultant in endocrinology at Tan Tock Seng Hospital and Adjunct Senior Lecturer at the Lee Kong Chian School of Medicine in Singapore. Under a strategic advisory agreement, Dr. Yong will guide scientific and development strategy, clinical oversight, strategic consultation, and trend analysis in endocrinology and chronic wound management, reinforcing Cuprina’s focus on patient safety and clinical excellence.
Cuprina Holdings (Cayman) Limited reported that it issued a press release on November 18, 2025 announcing the formation of a joint venture company with Aiodine Laboratory. The joint venture is intended to develop and market a novel iodine-based solution as a new wound care therapy. The press release describing this collaboration is included as Exhibit 99.1 to this Form 6-K.
Cuprina Holdings (CUPR) reported a change in its independent registered public accounting firm. The board dismissed Kreit & Chiu CPA LLP effective October 15, 2025, and appointed J&S Associate PLT as successor auditor to audit the consolidated financial statements for the fiscal year ending December 31, 2025. The audit committee approved the appointment.
K&C’s audit reports for 2024 and 2023 contained no adverse opinions or disclaimers and were not qualified or modified. The company stated there were no disagreements with K&C on accounting principles, disclosure, or audit scope during the two most recent fiscal years and through October 14, 2025, and no reportable events as defined in Item 16F(a)(1)(v) of Form 20-F. A letter from K&C addressing the disclosure was filed as an exhibit.
Cuprina Holdings (Cayman) Limited filed a Form 6-K to share that, on September 9, 2025, it issued a press release announcing that Cuprina has secured exclusive rights to Southeast Asia’s first medical waste recycling technology demonstrated by UNIDO and the Global Environment Facility (GEF). The report mainly serves as a regulatory notice that this press release has been furnished as an exhibit.
Cuprina Holdings (Cayman) Limited filed a Form 6-K to disclose a management change and related IP development step. The company announced that Dr. Ronald A. Sherman will become its Medical & Scientific Director effective 15 Sep 2025. Concurrently, Cuprina signed a licensing agreement with Dr. Sherman; however, the filing does not provide economic terms, duration, or scope of the licensed assets. No financial results, guidance, or other operational updates were included.
Cuprina Holdings (Cayman) Limited (CUPR) has filed a Form 6-K announcing the resignation of Mr. Baptista Carl Marc from his positions as Director and Chief Technology Officer, effective 30 June 2025. The company states that Mr. Baptista is leaving to pursue other business opportunities and that the departure is not due to any disagreement with the company on operational or governance matters. No successor or interim CTO has been named in the filing, and no additional financial information or strategic updates were provided.
Cuprina Holdings (Cayman) Limited filed a Form 6-K on 30 June 2025. The sole purpose of the submission is to furnish a press release (Exhibit 99.1) that offers an update on the company’s research studies conducted with three leading education institutes. Apart from confirming that the press release was issued and attaching it as an exhibit, the filing contains no financial statements, earnings data, major transactions, or other material disclosures. The document is therefore primarily administrative, indicating ongoing collaboration activity while fulfilling SEC disclosure requirements for foreign private issuers.